Provisions for Supervision of Drug Distribution
Commissioner of SFDA
Provisions for Supervision of Drug Distribution
(SFDA Decree No.26)
The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.
Shao Mingli
Commissioner of SFDA
January 31, 2007
Provisions for Supervision of Drug Distribution
Chapter I
Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.
Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.
Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.
Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.
Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.
Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors
Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.
Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.
Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.
Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.
Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.
Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.
Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.
Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.
Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.
Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.
The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.
Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.
Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.
Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.
Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.
Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.
A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.
Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.
Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.
Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.
When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.
Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.
Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.
Article 22 Any illegal purchase of drugs is prohibited.
Chapter III Supervision on Drug Purchase and Storage by Medical Institutions
Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.
Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.
Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.
Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.
Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.
A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.
Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.
Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.
Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.
Chapter IV Legal Liabilities
Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.
Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.
Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.
Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments,shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.
Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.
Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.
Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.
Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.
Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.
Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.
Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.
Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.
Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.
Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.
Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.
Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.
Chapter V Supplementary Provisions
Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.
Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.
Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.
海南省公共机构节能管理办法
海南省人民政府
海南省政府令第233号
《海南省公共机构节能管理办法》已经2010年10月25日第五届海南省人民政府第56次常务会议审议通过,现予以公布,自2011年1月1日起施行。
省长 罗保铭
二○一○年十一月九日
海南省公共机构节能管理办法
第一章 总 则
第一条 为推动我省公共机构节能,提高公共机构能源利用效率,降低运行成本,发挥公共机构在全社会节能中的表率作用,根据《中华人民共和国节约能源法》和《公共机构节能条例》,结合本省实际,制定本办法。
第二条 本办法所称公共机构,是指本省全部或者部分使用财政性资金的国家机关、事业单位和团体组织。
第三条 省人民政府管理机关事务工作的机构在省人民政府管理节能工作部门的指导下,负责推进、指导、协调、监督全省的公共机构节能工作。
市、县、自治县人民政府管理机关事务工作的机构在同级节能主管部门指导下,负责本级公共机构节能监督管理工作,指导和监督下一级公共机构节能工作。
教育、科技、文化、体育、卫生等行政主管部门应当在同级管理机关事务工作机构的指导下,组织开展本系统内公共机构节能工作。
第四条 县级以上人民政府管理机关事务工作的机构应当建立、健全公共机构节能工作的管理体系和协调机制,设立专门工作岗位,配备专职工作人员。
第五条 县级以上人民政府管理机关事务工作的机构应当会同有关部门,开展公共机构节能宣传、教育和培训,普及节能科学知识,提高全员节能意识,增强节能管理人员的专业知识和操作技能。
第六条 县级以上人民政府应当将公共机构节能相关工作经费纳入本级财政预算,节能技术和产品的推广应用、节能改造等支出纳入省节能专项资金统一管理。
第七条 公共机构应当加强用能管理,采取技术上可行、经济上合理的措施,降低能源消耗,减少、制止能源浪费,有效合理地利用能源。
第八条 公共机构主要负责人对本单位节能工作负总责。公共机构的节能工作实行目标责任制和考核评价机制。节能目标和指标完成情况应当作为对公共机构主要负责人考核评价的内容。
第二章 节能规划
第九条 省人民政府管理机关事务工作的机构应当会同有关部门,根据全省经济和社会发展规划制定全省公共机构节能中长期规划和本级公共机构节能计划,报省人民政府批准后实施。
市、县、自治县人民政府管理机关事务工作的机构应当根据全省公共机构节能中长期规划,结合实际,会同有关部门制定本级公共机构节能中长期规划,并按年度将规划确定的节能目标和指标分解落实到本级公共机构。市、县、自治县公共机构节能规划确定的节能目标和指标应当按年度分解落实到所辖乡(镇)、街道公共机构。
第十条 公共机构应当根据本级公共机构节能规划,结合本单位用能特点和上一年度用能状况,制定年度节能目标和实施方案。
公共机构应当将年度节能目标及实施方案,于每年1月31日前报本级人民政府管理机关事务工作的机构备案;县级以上人民政府管理机关事务工作的机构应当将本辖区年度节能目标和实施方案报上一级人民政府管理机关事务工作的机构备案。
第三章 节能管理
第十一条 公共机构应当确定人员担任本单位节能联络员,负责收集、整理、传递节能工作重要信息,按时报送能源消费统计情况。
第十二条 公共机构应当建立能源消耗计量制度,按照国家规定配备和使用经检验合格的能源计量器具,区分用能种类、用能系统实行能源消耗分户、分类、分项计量,并对能源消耗状况进行实时监测,及时发现纠正用能浪费现象。
第十三条 公共机构应当指定专人负责能源消耗统计,如实记录能源消耗计量原始数据,建立统计台账,通过分析总结形成上一年度能源消耗状况报告,并于每年3月31日前报送本级人民政府管理机关事务工作的机构。
各级人民政府管理机关事务工作的机构负责监测、统计、公示本行政区域内公共机构能耗状况。
第十四条 县级以上人民政府管理机关事务工作的机构应当会同有关部门按照管理权限,根据不同行业、不同系统公共机构能源消耗综合水平和特点,制定、公布、调整本级公共机构能源消耗定额,监督公共机构在能源消耗定额范围内使用能源,加强能源消耗支出管理。财政部门根据能源消耗定额制定能源消耗支出标准。
第十五条 公共机构应当按照国家有关强制采购或者优先采购的规定,采购列入节能产品、设备政府采购名录和环境标志产品政府采购名录中的产品、设备,不得采购国家明令淘汰的用能产品、设备。
第十六条 公共机构新建建筑和既有建筑维修改造应当严格执行国家有关建筑节能设计、施工、调试、竣工验收等方面的规定和标准,县级以上人民政府建设行政主管部门对执行国家有关规定和标准的情况应当加强监督检查。
县级以上人民政府建设行政主管部门,应当对本级公共机构建设项目进行节能评估和审查;未通过节能评估和审查的项目,不得批准或者核准建设。
第十七条 公共机构应当依照国家有关规定进行能源审计,对本单位用能系统、设备的运行及使用能源情况,进行技术和经济性评价,根据审计结果采取提高能源利用效率的措施。
第十八条 县级以上人民政府管理机关事务工作的机构应当会同建设行政主管部门,制定本级公共机构既有建筑节能改造计划并组织实施。
公共机构既有建筑进行改建、装修、加固时,应当同时考虑节能改造的内容,同步设计、同步施工、同步完成。严禁违反规定对既有建筑进行改建、扩建和超标准装修。〖HJ10mm〗
第四章 节能措施
第十九条 公共机构应当设立能源管理岗位,实行能源管理岗位责任制。重点用能系统、设备的操作岗位应当配备专业技术人员,专业技术人员应当参加管理机关事务工作的机构及相关部门组织开展的业务培训。
第二十条 公共机构可以采取合同能源管理方式,委托专业节能服务机构进行节能诊断、设计、融资、改造和运行管理。
第二十一条 公共机构选择物业服务企业时,应当考虑其节能管理能力。公共机构与物业服务企业订立物业服务合同,应当载明节能管理的目标和要求。
物业服务企业应当根据物业服务合同的约定,提出节能管理的具体措施。公共机构应当将节能目标完成情况,纳入评价物业服务企业服务质量的内容。
第二十二条 公共机构实施节能改造,应当在能源审计的基础上制定节能改造方案,并经评估后组织实施。节能方案应当明确节能指标,并在节能改造后采用计量方式对节能指标进行综合评价和考核。
第二十三条 公共机构新建建筑和既有建筑维修改造,应当按照本省规定统一配建太阳能热水系统。
公共机构既有建筑节能改造应当优先使用遮阳、充分利用自然通风等低成本改造措施。
第二十四条 公共机构应当建立、健全本单位节能运行管理制度和用能系统操作规程,加强用能系统和设备运行调节、维护保养、巡视检查,推行低成本、无成本节能措施。
公共机构应当根据有关规定,采取以下措施,加强用能管理:
(一)加强办公用电的管理,建立用电巡查制度,减少空调、计算机、复印机等用电设备的待机能耗;
(二)严格执行国家有关空调室内温度控制的规定,充分利用自然通风,改进空调运行管理,加强维护保养,提高空调能效水平;
(三)电梯系统应当实行智能化控制,合理设置电梯开启数量、楼层和时间,加强运行调节和维护保养;
(四)照明系统应当利用自然采光,使用高效节能照明灯具,优化照明系统设计,采用限时开启、间隔开灯等方式改进电路控制,推广应用智能调控装置,严格控制建筑物外部泛光照明以及外部装饰用照明;
(五)网络机房、食堂、开水间、锅炉房等部位的用能情况应当实行重点监测,进行科学管理,采取有效措施降低能耗。
第二十五条 公共机构应当加强内部信息化、网络化建设,推进无纸化办公,合理控制会议数量与规模,健全完善电视电话会议、网络视频会议等系统,提高工作效率,节约人力物力,降低能源消耗。
第二十六条 公共机构应当采取以下措施,加强车辆节能管理:
(一)对公务用车实行编制管理,严格控制车辆规模;
(二)按照标准配备公务用车,优先选用低能耗、低污染、使用清洁能源的车辆,并严格执行车辆报废制度;
(三)按照规定用途使用公务用车,制定公务用车登记制度,严禁公车私用,严格实行公务用车定点加油、定点维修等制度;
(四)严格执行车辆百公里油耗分类控制标准,推行单车能耗核算制度;
(五)推进公务用车服务社会化,加快机关班车、接待用车和公务用车改革,鼓励工作人员利用公共交通工具、非机动交通工具出行。
第二十七条 公共机构应当积极推广、应用节能新产品、新技术和新能源,加快淘汰高能耗用能产品、设备,做好淘汰产品、设备的回收处理和再利用工作。〖HJ10mm〗
第五章 节能监督和保障
第二十八条 公共机构的节能工作应当接受社会监督。任何单位和个人都有权举报公共机构浪费能源的行为。
第二十九条 县级以上人民政府管理机关事务工作的机构,应当设立节能举报电话,接受社会公众对于浪费能源行为的举报,并对举报及时调查处理。
第三十条 县级以上人民政府管理机关事务工作的机构,应当会同有关部门,加强对本级公共机构节能的监督检查。监督检查的内容包括:
(一)年度节能目标和实施方案的制定、落实情况;
(二)能源消耗计量、监测和统计情况;
(三)能源消耗定额执行情况;
(四)节能管理规章制度建立及落实情况;
(五)能源管理岗位设置以及能源管理岗位责任制落实情况;
(六)开展能源审计情况;
(七)用能系统、设备节能运行情况;
(八)节能产品、设备的政府采购情况;
(九)公务用车的节能管理情况。
第三十一条 县级以上人民政府管理机关事务工作的机构应当对节能规章制度不健全、超过能源消耗定额使用能源情况严重的公共机构,进行重点监督检查。
第三十二条 县级以上人民政府管理机关事务工作的机构依法实施节能监督检查时,公共机构应当积极配合。
第三十三条 县级以上人民政府管理机关事务工作的机构应当会同有关部门制定本级公共机构节能评价考核办法,建立公共机构考核激励机制,每年对上一年度公共机构节能任务和节能目标完成情况进行检查和考核评价。
第六章 奖励与惩处
第三十四条 县级以上人民政府对在公共机构节能工作中作出显著成绩的单位和个人,按照有关规定予以表彰和奖励。
第三十五条 公共机构有下列行为之一的,由本级人民政府管理机关事务工作的机构会同有关部门责令限期改正;逾期不改正的,予以通报,并由相关部门对公共机构负责人依法给予处分:
(一)未制定年度节能目标和实施方案,或者未按照规定将年度节能目标和实施方案备案的;
(二)未实行能源消耗计量制度,或者未区分用能种类、用能系统实行能源消费分户、分类、分项计量,并对能源消耗状况进行实时监测的;
(三)未建立健全能源消费统计制度、能源消费状况报告和节能联络员工作制度的;
(四)开工建设未通过节能评估和审查的公共机构建设项目,或者违反国家有关规定和标准以节能改造的名义改建、扩建办公用房和进行超标准装修的;
(五)超过能源消耗定额使用能源,未向本级人民政府管理机关事务工作的机构作出说明的;
(六)未按规定设立能源管理岗位,未实行能源管理责任制,或者未在重点用能系统、设备操作岗位配备专业技术人员的;
(七)未按照规定进行能源审计,或者未根据审计结果采取提高能源利用效率措施的;
(八)拒绝、阻碍依法实施节能监督检查的。
第三十六条 公共机构违反规定超标准、超编制购置公务用车,或者不如实报告公务用车数量,或者拒不报废高耗能、高污染车辆的,对直接负责的主管人员和其他直接责任人员依法给予处分,并由本级人民政府管理机关事务工作的机构依照有关规定,对车辆采取收回、拍卖、责令退还等方式处理。
第三十七条 公共机构违反规定用能造成能源浪费的,由本级人民政府管理机关事务工作的机构会同有关部门予以通报,并下达节能整改意见书;未按节能整改意见书整改或者情节严重的,由相关部门对其直接负责的主管人员和其他直接责任人员依法给予处分。〖HJ10mm〗
第七章 附 则
第三十八条 本办法的具体应用问题,由省人民政府管理机关事务工作的机构负责解释。
第三十九条 本办法自2011年1月1日起施行。